Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objective The in vitro activity of isavuconazole was determined for 1677 Candida and 958 Aspergillus isolates from 2012 to 2014 with voriconazole as comparator. Methods Aspergillus isolates were screened for resistance using azole-agar. Aspergillus isolates that screened positive and all Candida isolates underwent EUCAST broth microdilution testing. Isolates were categorized as wild-type (wt) or non-wt, adopting EUCAST epidemiological cut-off values (ECOFFs) (where available) or wt upper limits (wtULs; two two-fold dilutions above the MIC 50 ). The CYP51A gene was sequenced for non-wt Aspergillus fumigatus isolates. Itraconazole and posaconazole MICs were determined for selected Aspergillus isolates with isavuconazole MIC ≥2 mg/L. Results Isavuconazole MIC 50 (range) (mg/L) against Candida species were: Candida albicans : ≤0.03 (≤0.03 to >4), Candida dubliniensis : ≤0.03 (≤0.03), Candida glabrata : ≤0.03 (≤0.03–4), Candida krusei : 0.06 (≤0.03–0.5), Candida parapsilosis : ≤0.03 (≤0.03–0.06), Candida tropicalis : ≤0.03 (≤0.03 to >4), Saccharomyces cerevisiae (anamorph: Candida robusta ): ≤0.03 (≤0.03–0.5). Non-wt isavuconazole/voriconazole MICs were found for C. albicans : 0.8/1.0%, C. dubliniensis : 0/1.8%, C. glabrata : 14.9/9.5%, C. krusei : 2.7/1.4%, C. parapsilosis : 1.7/1.8%, C. tropicalis : 14.3/19.1% and S. cerevisiae : 10.0/0%. Isavuconazole MIC 50 (range) (mg/L) against Aspergillus species were: A. fumigatus : 1 (≤0.125 to >16), Aspergillus niger : 2 (1–8), Aspergillus terreus : 1 (0.25–8), Aspergillus flavus : 1 (0.5–2), Aspergillus nidulans : ≤0.125 (≤0.125–0.25). Non-wt isavuconazole/voriconazole MICs were found for 13.7/15.2% A. fumigatus , 4.9/0% A. niger and 48.2/22.2% A. terreus . Conclusion Isavuconazole displayed broad in vitro activity, similar to that of voriconazole. Up to 15% of C. glabrata , C. tropicalis and A. fumigatus isolates were non-wt, reflecting increased resistance at a reference centre and technical issues. Significant CYP51A alterations were reliably detected applying the isavuconazole breakpoint.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Maertens, J. A., Raad, I. I., Marr, K. A., Patterson, T. F., Kontoyiannis, D. P., Cornely, O. A., Bow, E. J., Rahav, G., Neofytos, D., Aoun, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01159-9 · Cited by 1,001
Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus
van der Linden, J. W. M., Arendrup, M. C., Warris, A., Lagrou, K., Pelloux, H., Hauser, P. M., Chryssanthou, E., Mellado, E., Kidd, S. E., Tortorano, A. M., et al. (2015) · Emerging Infectious Diseases · doi:10.3201/eid2106.140717 · Cited by 371 · cited 1×
“3% and equal to the overall average [25].”
BackgroundSelf-citationArendrup, M. C., Dzajic, E., Jensen, R. H., Johansen, H. K., Kjaldgaard, P., Knudsen, J. D., Kristensen, L., Leitz, C., Lemming, L. E., Nielsen, L., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12212 · Cited by 206 · cited 1×
“Identification was done using macro- and micromorphology, supplemented by thermo-tolerance (incubation at 37 C and 43 C) and matrixassisted laser desorption/ionization time-of-flight mass spectrometry (Bruker, Bremen, Germany) for Candida [13] and by thermotolerance (incubation at 50 C) for Aspergillus fumigatus compl…”
MethodSelf-citationArendrup, M. C., Garcia-Effron, G., Lass-Flörl, C., Lopez, A. G., Rodriguez-Tudela, J.-L., Cuenca-Estrella, M., & Perlin, D. S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01256-09 · Cited by 158 · cited 1×
“In such cases, the lowest concentration tested was chosen as the wtUL [19].”
MethodSelf-citation
Cited by
Dudakova, A., Spiess, B., Tangwattanachuleeporn, M., Sasse, C., Buchheidt, D., Weig, M., Groß, U., & Bader, O. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00095-16 · Cited by 113
Desnos-Ollivier, M., Lortholary, O., Bretagne, S., & Dromer, F. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02615-20 · Cited by 44
“lusitaniae can be considered susceptible in vitro to fluconazole, voriconazole, and posaconazole (14, 16, 18, 19, 21), while (i) C.”
BackgroundSpecial considerations for the diagnosis and treatment of invasive pulmonary aspergillosis
McCarthy, M. W., & Walsh, T. J. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1340835 · Cited by 8
Metadata
- Authors
- Astvad, K. M. T., Hare, R. K., & Arendrup, M. C.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 23
- Issue
- 11
- Pages
- 882-887
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W2598411000
- Cited by
- 48
- References
- 5
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates. https://app.cochat.ai/papers/10.1016/j.cmi.2017.03.023
- The paper
- Astvad, K. M. T., Hare, R. K., & Arendrup, M. C. (2017). Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2017.03.023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.